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Summary 
Human CD4 § T cells, activated by allogeneic monocytes in a primary mixed lymphocyte reac- 
tion in the presence of exogenous interleukin (IL)  10, specifically failed to proliferate after re- 
stimulation with the same alloantigens. A comparable state of T  cell unresponsiveness could be 
induced  by  activation  of CD4 +  T  cells  by  cross-linked  anti-CD3  monoclonal  antibodies 
(mAbs)  in the presence of exogenous IL-10. The anergic T  cells failed to produce IL-2, IL-5, 
IL-10, interferon %  tumor necrosis factor el, and granulocyte/macrophage colony-stimulating 
factor. The IL-10--induced anergic state was long-lasting. T  cell anergy could not be reversed 
after restimulation of the cells with anti-CD3 and anti-CD28 mAbs, although CD3 and CD28 
expression was normal. In addition, restimulation ofanergized T cells with anti-CD3 mAbs in- 
duced normal Ca  2+ fluxes and resulted in increased CD3, CD28, and class II major histocom- 
patibility complex expression, indicating that  calcineurin-mediated signaling occurs in these 
anergic  cells.  However,  the  expression of the  IL-2  receptor o~  chain was  not  upregulated, 
which may account for the failure of exogenous IL-2 to reverse the anergic state.  Interestingly, 
anergic T cells and their nonanergic counterparts showed comparable levels of  proliferation and 
cytokine production after activation with phorbol myristate acetate and Ca  2+ ionophore, indi- 
cating that a direct activation of a protein kinase C-dependent pathway can overcome the tol- 
erizing effect oflL-10. Taken together, these data demonstrate that IL-10 induces T cell anergy 
and therefore may play an important role in the induction and maintenance of antigen-specific 
T  cell tolerance. 
I 
L-10 has  been shown to inhibit antigen-specific activa- 
tion and proliferation of human peripheral blood T  cells 
and T  cell clones belonging to the Th0, Thl, or Th2 subsets 
(1, 2). These inhibitory effects were indirect and mediated 
through inhibition of the  function of APCs  (3-6).  IL-10 
regulates constitutive and IFN-~/- or IL-4---induced  class II 
MHC expression on monocytes, dendritic cells and Langer- 
hans cells  (2, 7). In addition, IL-10 inhibits the expression 
of CD54 (intercellular adhesion molecule-I, the ligand for 
LFA-1), CD80, and CD86 (ligands for CD28) which func- 
tion as important costimulatory molecules for T  cell activa- 
tion (8-10).  More recently, it has been shown that IL-10 
also has a direct effect on CD4 + T  by suppressing IL-2 se- 
cretion (11,  12). 
Similar to its inhibitory effects on T  cell proliferation in 
response  to  soluble  antigens,  IL-10  strongly reduced the 
proliferation of human alloreactive cells in mixed lympho- 
cyte reactions  (MLR) 1,  and  the  levels  of cytokines pro- 
1Abbreviations used in this paper: [Ca2+]i, intercellular  calcium; MLR, mixed 
lymphocyte  reaction. 
duced  in  these  MLR  were  significantly  reduced  in  the 
presence of exogenous IL-10 (13).  In addition, IL-10 sup- 
pressed the  proliferative responses  of CD4 +  allogeneic T 
cell clones.  In parallel with the  reduced proliferation, re- 
ductions in the levels of IL-2, IL-5, GM-CSF, and IFN-~/ 
production by these T  cell clones were observed (14). 
Recently, we showed that in SCID patients successfully 
transplanted  with  HLA-mismatched  hematopoietic  cells, 
CD4 + T cell clones specifically recognizing the host alloan- 
tigens produce very low levels of IL-2 after antigenic stim- 
ulation, but secrete high amounts of IL-10, which partially 
inhibits  their  proliferation  in  vitro  (15).  Furthermore, 
PBMC  from  these  SCID  patients  express  considerably 
higher levels of IL-10 transcript compared with PBMC of 
normal  controls, especially in the  non-T cell subset  (15). 
These  results  suggest  that  the  high  expression  of IL-10 
detected in SCID human chimeras may play a key role in 
the maintenance of in vivo tolerance, by inducing an aner- 
gic state in donor-derived T  cells specific for the host allo- 
antigens. 
Optimal activation and expansion of alloreactive T  cells 
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stimulatory signals provided by one or more accessory mol- 
ecules  expressed  on  alloantigen-presenting cells.  Engage- 
ment of the TCIK by antigens without costimulation results 
in T  cell  anergy  (16-19).  This  state  of unresponsiveness 
may also be induced in vitro in long-term T  cell clones by 
stimulation with agents that mimic TC1K occupancy, in the 
absence of CD28  signaling, and/or by inhibition of IL-2 
secretion by T  cells (16-19). The observation that high lev- 
els  of IL-10  are  associated with  transplantation tolerance, 
and that this cytokine has been shown to inhibit both the 
antigen-presenting and  accessory  function  of monocytes 
and IL-2 production by T  cells, suggest that IL-10 may be 
involved in the induction of anergy in CD4 + T  cells. 
In the present study, we  demonstrate that IL-10 is able 
to  induce a  long-lasting antigen-specific unresponsiveness 
against allogeneic antigens that cannot be reversed by IL-2 
or CD28 stimulation. 
Materials  and Methods 
Cells.  PBMC  were  prepared by centrifugation over Ficoll- 
Hypaque.  CD4 §  T  cells were  purified by  negative  selection. 
Negative purification was performed using a cocktail of antibod- 
ies  directed  against  non-CD4  +  T  cells: CD8,  CD14,  CD16, 
CD19, CD20, CD56, and HLA-DR. Cells were incubated with 
saturating  amounts of antibodies for 20 rain at 4~  After wash- 
ing,  Dynabeads  (Dynal,  Oslo,  Norway)  were  added  at  a  10:1 
bead/target cell ratio  and incubated for  1 h  at  4~  Beads  and 
contaminating cells were  removed by magnetic field.  The  re- 
maining cells were resuspended with the same amount of beads 
and a second incubation period of 1 h at 4~  was performed. Af- 
ter removing contaminating  cells, CD4 § T cells were analyzed by 
FACScan  |  (Becton Dickinson & Co., Mountain View, CA) and 
revealed to be ~90-95% positive. Monocytes were purified using 
the same procedure with an antibody cocktail  containing CD2, 
CD3, CD8, CD16, CD19, CD20, and CD56. These monocytes 
were ~95% CD14 § by FACScan  |  analysis. In some experiments, 
CD4 § T  cells were purified by positive selection using magnetic 
beads directly coated with CD4 mAbs, according to the manufac- 
turer's instructions  (Dynal). With this procedure,  cells were ~95% 
pure. 
Reagents.  Purified  recombinant  IL-10  was  provided  by 
Schering-Plough Research Institute (Kenilworth, NJ).  The anti- 
IL-2tL mAb B-B10 (20) and anti-CD3 mAb SPV-T3 (21) were 
previously described.  Nonconjugated, PE- or FlTC-conjugated 
CD28,  CD2,  CD3,  CD4,  CD8,  CD14,  CD16,  CD19,  CD20, 
CD56, HLA-DR, and controls mAbs of the appropriate  isotypes 
were purchased from Becton Dickinson & Co. 
Proliferation Assays.  In all proliferation assays, cells were cul- 
tured in Yssel's medium (22) supplemented with 10% FCS and 1% 
human serum.  For MLP,., purified CD4 + T  cells (5  ￿  104 cells/ 
well)  were stimulated with purified allogeneic  monocytes (5  ￿ 
104 cells/well) or with irradiated PBMC (105 cells/well) in 200-btl 
flat-bottomed 96-well plates  (Falcon; Becton Dickinson & Co., 
Lincoln Park,  NJ).  PBMC used as stimulators  were irradiated  at 
4,000 rad. 
For cross-linked anti-CD3 mAb activation,  500 ng/ml ofanti- 
CD3 mAbs diluted in 0.1 M  Tris buffer, pH 9.5, was incubated 
for 1 wk at 4~  in flat-bottomed 96- or 24-well plates. These ex- 
perimental conditions were found to be optimal in experiments 
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in which different  concentrations of antibodies and different  in- 
cubation times were tested. After washing the plates three times, 
CD4  + T cells were added at 5 ￿  104 cells/well. 
For activation with PMA plus Ca  2+ ionophore (A23187 Sigma 
Chemical Co.,  St.  Louis,  MO),  cells were cultured at  5  ￿  104 
cells/well and activated for 3 d with PMA (1 ng/rnl) and A23187 
(500 ng/ml). 
To measure the proliferation of T cells, cells were cultured for 
72  h  or 5 d for MLR experiments at 37~  in 5% CO2,  subse- 
quently pulsed with [3H]TdlK for 12 h, and harvested as described 
previously (15). All tests were carried out in triplicate. 
Induction of Anergy.  To  induce anergy,  CD4 +  T  cells were 
cultured at 2.5  X  105  cells/ml in 24-well plates  (Linbro;  ICN 
Biomedicals,  Inc., Aurora, Ohio) and activated  either with puri- 
fied allogeneic monocytes or cross-linked anti-CD3 mAbs in the 
presence of IL-10 (100 U/ml). After different incubation periods 
(ranging from 3 to 10 d, see below), cells were collected,  layered 
on  a  Ficoll-Hypaque gradient  to  remove  dead  cells, washed 
twice,  and  restimulated  with  irradiated  allogeneic  PBMC  or 
cross-linked anti-CD3 mAbs. 
Immunofluorescence Analysis.  For detection of cell surface anti- 
gens, 10  s cells were labeled with PE- or FITC-conjugated mAbs. 
Cells were incubated for 30 rain with the appropriate  antibody at 
4~  in PBS  with 0.1%  BSA  and 0.02  mM  NaN  3.  After  three 
washes, the labeled cell samples were analyzed on a FACScan  | 
Determination of Lymphokine Production.  0.5  ￿  106 cells were 
stimulated by cross-linked anti-CD3 mAbs (10 txg/ml),  by PMA 
and Ca  2+ ionophore (A23187), or by allogeneic monocytes (1  X 
106) for 24 h. The secretion of IL-2, IL-4, IL-5, IL-10, TNF-e~, 
IFN-',/, and GM-CSF was measured by immunoenzymetric as- 
says performed as previously described  (15, 23). The sensitivity of 
the various ELISAs was 20 pg/ml for IL-2, 40 pg/ml for IL-4 and 
IL-5, 50 pg/ml for GM-CSF and IL-10, and 100 pg/ml for IFN-~/ 
and TNF-er 
Calcium Mobilization Studies.  Mobilization ofintracellular cal- 
cium ([Ca2+]i) in anergic cells loaded with indo-1/AM was assessed 
using standard fluorometry. Cells were loaded with 2 I.LM indo- 
1/AM in complete growth medium at 20~  for 45  min. Cells 
were then washed,  resuspended  in Na-HBSS (in mM: 2 CaC12, 
145 NaC1, 5 KC1, 1 MgC12, D-glucose, and 20 Hepes,  pH 7.3) 
containing 1% BSA and maintained at 20~  for up to 2 h. Ap- 
proximately 5 X 105 cells were then suspended in 2 ml Na-HBSS 
and maintained at  37~  in a  constantly stirred  acrylic  cuvette. 
Anti-CD3 mAbs (1  Dg/ml) were added  followed by goat  anti- 
mouse Ig to cross-link the anti-CD3 mAbs on the cell surface. 
No Ca  2+ fluxes were detected in the absence of cross-linking, ei- 
ther in anergic or in control cells. Fluorescence measurements to 
determine [Ca2+]i were made using a Spectrofluorimeter (Photon 
Technologies Inc., South Brunswick, NJ). 
Results 
IL-IO  Induces Alloantigen-specific  T  Cell  Unresponsiveness. 
As shown previously (13), IL-10 partially inhibits the prolif- 
eration of peripheral blood CD4 + T  cells in response to al- 
logeneic monocytes in a primary MLtL (Fig. 1 a).  This in- 
hibition was comparable with that induced by anti-IL-21k 
ix chain mAbs (anti-CD25 mAbs). To determine whether 
prolonged incubation of the  alloantigen-stimulated CD4 + 
T  cells in IL-10 might also downregulate their proliferative 
responses after restimulation, the cells were kept in culture 
in the presence or absence oflL-10 for 10 d  (Fig. 1 b). No 25 
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Figure  1.  IL-10 induces alloantigen-specific anergy in CD4 + T  cells in 
MLR. (a) [3H]TdR incorporation of purified CD4 + T  cells cultured for 3 d 
in medium alone (white bar) or stimulated in a primary MLtk with aUo- 
geneic purified monocytes (gray bar) in the presence of IL-10 (100 U/ml; 
black  bar) or  the anti-IL-2R~x chain mAb B-B10  (hatched  bar).  (b)  The 
three different bar sets represent cells  that have been preactivated as de- 
scribed in a, kept in culture for 10 d, washed, and restimulated with either 
medium alone (black  bars),  allogeneic irradiated  PBMC  isolated from a 
third-party donor different from that of the monocytes used in the preac- 
tivation step (PBMC-2, crosshatched bars), allogeneic irradiated PBMC iso- 
lated from the same donor used in the preactivation step (PBMC-1, gray 
bars),  PBMC-1  plus IL-2 (20 U/ml;  black-hatched  bars),  or PBMC-1 plus 
anti-CD28 mAbs (10 I.Lg/ml; hatched  bars). All  measurements were done 
in triplicate; one representative experiment out of five is shown. 
significant cell death was observed in either culture  condi- 
tion, and comparable cell numbers were harvested at termi- 
nation  of the assays (not shown).  After this  culture period, 
CD4 +  control  T  cells  stimulated  with  alloantigens  in  the 
absence of IL-10 reached a resting state and could be fully 
reactivated  by the  same  allogeneic  irradiated  PBMC  in  a 
secondary MLR, or by third-party allogeneic monocytes in 
a primary MLtk (Fig.  1 b). In contrast,  CD4 + T  cells incu- 
bated in the presence oflL-10 failed to proliferate in a sec- 
ondary  MLR  in  response  to  the  same  allogeneic  PBMC, 
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but  they retained  their  capacity to proliferate  normally  to 
third-party alloantigens in a primary MLR.  This unrespon- 
sive  state  could  not  be  reversed  by  saturating  concentra- 
tions of exogenous IL-2 (20 U/ml) or by anti-CD28  mAbs 
(10 p,g/ml). Furthermore,  this state ofT  cell unresponsive- 
ness is specific for IL-10 and is not due to inhibition  of the 
primary MLR,  since CD4 +  T  cells incubated  in  the pres- 
ence  of anti-CD25  mAbs  (10  p,g/ml)  for  10  d  exhibited 
proliferative responses that were comparable with those of 
their untreated counterparts. 
IL- I O Induces an Anergic State in CD4 + T  Cells Activated by 
Anti-CD3 mAbs.  Next, we analyzed whether the  IL-10-- 
induced  anergy reflected a direct effect of IL-10 on CD4 § 
T  cells.  For this purpose,  highly purified peripheral  blood 
CD4 +  T  cells  were  activated  by  cross-linked  anti-CD3 
mAbs in  the  presence  or  absence  of exogenous  IL-10 for 
10 d. A  direct effect oflL-10 on CD4 + T  cell proliferation 
was observed  (11,  12),  and this inhibitory  effect was com- 
parable  with  that  induced  by anti-CD25  mAbs  (Fig.  2  a). 
Activation of the CD4 + T  cells in the presence oflL-10 re- 
sulted  in  a  profound  state  of T  cell  unresponsiveness  that 
could  not  be  reversed  by  exogenous  IL-2  or  anti-CD28 
mAbs  (Fig.  2  b).  However,  anergic  cells proliferated  nor- 
really  in  response  to  stimulation  by  Ca  2+  ionophore  and 
PMA.  These results indicate  that IL-10 induces  an anergic 
state in CD4 + T  cells, but that these cells respond normally 
to  signals  circumventing  TCR  activation.  This  induction 
of anergy is IL-10 specific, similar to IL-10-induced  T  cell 
unresponsiveness  to alloantigens,  and not related to inhibi- 
tion  of cell proliferation,  since  CD4 +  T  cells incubated  in 
the presence ofanti-CD25  mAbs for 10 d proliferated nor- 
really  in  response  to  restimulation  with  crosslinked  anti- 
CD3  mAbs.  The  induction  of anergy by IL-10 was  dose 
dependent  with  maximal  effects  observed  at  100  U/ml 
(Fig.  3).  Cells that had been  activated by anti-CD3  mAbs 
and  cultured  in the presence  or absence  of IL-10 for 10 d 
were in a resting state, and no apoptotic cell death was ob- 
served  in  the  control  or  IL-10-treated  cell  cultures  (not 
shown).  Thus,  IL-10 induces  a  comparable  state  of T  cell 
anergy  in  alloantigen-specific  and  anti-CD3-stimulated 
CD4 §  T  cells. 
Kinetics of Anergy Induction by IL-10.  To  determine  the 
kinetics  of induction  of T  cell anergy,  CD4 +  T  cells were 
activated with cross-linked anti-CD3 mAbs in the presence 
or  absence  of  IL-10  and  restimulated  at  different  time 
points after initiation  of the cultures  (Fig. 4). CD4 + T  cells 
cultured in the presence oflL-10 for only 3 d already failed 
to  proliferate  in  response  to  reactivation  by  cross-linked 
anti-CD3  mAbs.  Interestingly,  the  anergic  state  of these 
cells could still be reversed by exogenous  IL-2  (20  U/ml) 
or anti-CD28  (10 p,g/ml).  In contrast,  incubation  of the T 
cells with  IL-10 for 9-10  d  resulted in a  complete state  of 
anergy that could not be reversed by the addition  of either 
IL-2  or  anti-CD28  mAbs.  These  results  indicate  that  T 
cells activated  through  their TCtk/CD3  complexes in the 
presence  of IL-10  acquire  different  degrees  of unrespon- 
siveness, depending  on how long they have been  exposed 
to IL-10. a 
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Figure 2.  IL-10  induces polyclonal anergy in CD4+T cells activated 
with CD3 mAb. (a)  [3H]TdR incorporation of purified CD4  + T  cells 
cultured for 3 d in medium alone (white bar) or stimulated with cross- 
linked anti-CD3 mAbs (500 ng/ml; black bar) in the presence of IL-10 
(100 U/ml; cross-hatched bar) or  the  anti-IL-2R0t chain mAb B-B10 
(hatched bar). (b) The three different  bar sets represent cells that have been 
preactivated as described in a, kept in culture for 10 d, washed, and re- 
stimulated with either medium alone (black bars), cross-linked  anti-CD3 
mAbs (gray bars), anti-CD3 mAbs plus IL-2 (20 U/m]; crosshatched bars), 
anti-CD3 mAbs plus anti-CD28 mAbs (10 ~g/ml; black-hatched bars) or 
PMA (1 ng/m]) plus Ca  2+ ionophore (A23187, 500 ng/ml) (white bars). 
All measurements  were done in tripficate; one representative  experiment 
out of five is shown. 
IL- 10 Induced  T  Cell Anergy Is Long-lasting.  To determine 
the duration of the IL-10-induced anergic state in CD4 + T 
cells after removal of IL-10, the  cells were  activated with 
cross-linked anti-CD3 mAbs in the presence or absence of 
IL-10 for 10 d. After this incubation period, the cells were 
washed and recultured for 24 d in the presence of low con- 
centrations (2 U/ml) of exogenous IL-2 for optimal main- 
tenance of the T  cells over prolonged culture periods, but 
in the absence of IL-10. These T  cells were collected every 
other day during the culture period, washed, and restimu- 
lated  with  anti-CD3  mAbs.  T  cells  that  previously  had 
been incubated with IL-10 failed to proliferate even 24 d 
after removal of IL-10 (Fig. 5).  In contrast, control CD4 + 
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Figure  3.  Dose-dependent effect of IL-10 on  anergy induction in 
CD4 + T cells. CD4 + T cells were activated for 10 d with cross-linked 
anti-CD3 mAbs  in the presence of medium alone, IL-10 (5 U/ml), IL-10 
(20 U/m]),  or IL-10 (100 U/ml), as indicated.  After 10 d, cells were col- 
lected, washed, and restimulated with medium alone (white bars), cross- 
linked anti-CD3 mAbs (black bars), cross-linked  anti-CD3 mAbs plus IL-2 
(20 U/ml; hatched bars), or PMA plus Ca  2+ ionophore (black hatched bars). 
All measurements  were made in triplicate; one representative  experiment 
out of three is shown. 
T  cells that had been activated by anti-CD3 mAbs in the 
absence of IL-10, and maintained in the absence of IL-10 
for  24  d,  proliferated normally in response to  stimulation 
with  anti-CD3  mAbs.  In  addition,  the  unresponsiveness 
observed  after  culturing the  IL-10--treated cells  for  24  d 
could not be reversed by IL-2 (20 U/ml) or anti-CD28 (10 
p~g/ml) mAbs. These results indicate that IL-10-induced T 
cell anergy is profound and long-lasting. 
Anergized  T  Cells Fail to Secrete Cytokines.  T  cell anergy 
is generally defined as a failure of T  cells to proliferate and 
to produce IL-2 in response to triggering of the TCR  (18). 
To determine whether T  cells rendered unresponsive after 
activation with  either  allogeneic monocytes or  anti-CD3 
mAbs in the presence of IL-10 retained their ability to se- 
crete cytokines, we analyzed their cytokine production af- 
ter  restimulation with  the  same  allogeneic  monocytes or 
anti-CD3 mAbs, respectively. T  cells that were rendered un- 
responsive after activation by either alloantigens plus IL-10 
or anti-CD3 mAbs plus IL-10 failed to produce detectable 
amounts of IL-2,  IL-4,  IL-5,  IL-10,  TNF-oL,  IFN-%  or 
GM-CSF at 24 h  (Table 1)  or 48 h  (not shown)  after re- 
stimulation with the relevant allogeneic monocytes or anti- 
CD3  mAbs.  In  contrast,  the  untreated control cells pro- 
duced  levels  of IL-2,  IL-5,  IL-10,  IFN-%  TNF-c(,  and 
GM-CSF that  were  comparable with  those  of a  panel of 
CD4 + T  cells derived from different donors and stimulated 
in similar fashion (not shown). However, these cells did not 
secrete detectable levels of IL-4 (Table 1). 
As shown in Fig. 2, activation with PMA and Ca  2+ ion- 
ophore completely reversed  IL-10-induced unresponsive- 
ness of anti-CD3-activated T  cells. In Table t, it is shown 
that activation of anergic T  cells by PMA and Ca  2+  iono- 
phore for 24 h  also resulted in levels of IL-2, IL-5, IL-10, 
IFN-% and TNF-ot production that were comparable with 
those of their nonanergized counterparts. 
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Figure  4.  Kinetics  of anergy 
induction by IL-10 in CD4  + T 
cells. CD4 + T  cells were acti- 
vated  with  cross-linked  anti- 
CD3 mAbs in the absence (white 
bars) or presence (black bars) of 
IL-10 (100 U/ml).  After differ- 
ent incubation periods, ranging 
from 3 to 10 d as indicated, cells 
were collected, washed, and re- 
stimulated with  either medium 
alone,  cross-hnked anti-CD3 
mAbs,  cross-linked  anti-CD3 
mAbs  plus IL-2 (20  U/ml), 
cross-linked  anti-CD3  mAbs 
plus anti-CD28 mAbs (10  Ixg/ 
ml), or  PMA  plus Ca  2+  iono- 
phore.  All  measurements were 
done in triplicate and one repre- 
sentative experiment out of three 
is shown. 
Anergic  T  Cells  Fail  to  Express  CD25  after  Activation. 
Phenotypic analysis of T  cells rendered anergic after activa- 
tion by anti-CD3 mAbs in the presence of IL-10 revealed 
no  major  differences  as  compared  with  their  untreated 
counterparts, with the  exception of a  decrease  in the  IL- 
2Ro~ chain (CD25) expression on the anergic T  cells (Figs. 
6 and 7, a and b). No modulation of CD3 or CD28 expres- 
sion was observed on anergic cells, and activation by cross- 
linked anti-CD3 mAbs enhanced CD3, CD28, and class II 
MHC  expression  to  the  same  extent  as  on  control  cells 
(Fig. 6).  These data exclude the possibility that the T  cell 
unresponsiveness was  related  to  defective  TCR/CD3  or 
CD28  expression  and  show  that  signaling through  the 
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Figure  5.  Anergy  induced by IL-10 in CD4 + T cells is long-lasting. 
CD4  + T cells were activated with cross-linked  anti-CD3 mAbs  in the ab- 
sence (white bars) or presence (black bars) oflL-10 (100 U/ml) for 10 d. Af- 
ter 10 d, cells  were collected, washed, and cultured in the presence of IL-2 
(2 U/ml). 24 d later, cells  were collected and reactivated  with cross-linked 
anti-CD3 mAbs, cross-linked  anti-CD3 mAbs  plus IL-2 (20 U/ml), cross- 
linked anti-CD3 mAbs plus anti-CD28 mAbs (10 Ixg/ml), or PMA plus 
Ca  2+ ionophore. The results show one representative experiment out of 
three. 
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TCR./CD3 complex, which is insufficient for T  cell prolif- 
eration, still occurs in these anergized T  cells. 
However, in contrast to the control cells, the anergic T 
cells failed to upregulate IL-2Ro~ chain expression, indicat- 
ing that inhibition of IL-2RIx chain expression is a specific 
property of anergized T  cells (Fig. 7  b). The defect in up- 
regulation of CD25  expression was  observed  also  in the 
presence of exogenous IL-2, and correlated with the failure 
of IL-2 to reverse T  cell anergy induced by 8-10 d of incu- 
bation with IL-10 (Fig. 4). In contrast, T  cells rendered un- 
responsive  after  incubation with  IL-10  for  3  d  still  ex- 
pressed  considerable  levels  of  CD25  (Fig.  7  a).  Slight 
upregulation of CD25 was also observed after restimulation 
by anti-CD3 mAbs, but the levels of expression were still re- 
duced as compared with untreated cells.  However, addition 
oflL-2, which was able to reverse the anergic state, resulted 
in comparable levels of CD25 expression on control T  cells 
and T  cells incubated in the presence of IL-10 for 3 d  (Fig. 
7 a). 
Anti-CD3  mAbs  Induce  Normal  Ca 2+  Fluxes  in Anergic  T 
Cells.  The notion that signaling through the TCP,,/CD3 
complex occurs in anergic T  cells was confirmed by mea- 
suring the  induction of Ca  2+  fluxes  in  these  cells.  After 
loading with  Indo-1,  cells were  activated with  anti-CD3 
mAbs cross-linked by goat  anti-mouse Ig,  as indicated in 
Fig. 8. Ca  2§ fluxes induced in anergized T  cells after activa- 
tion with  cross-linked anti-CD3 mAbs were  comparable 
with those in untreated control T  cells (Fig. 8).  The load- 
ing of the anergic and control cells with Indo-1 was equiv- 
alent, as shown by the  comparable rise of Ca  2§  fluxes in- 
duced in the cells by addition of Ca  2§ ionophore (Fig. 8). 
Discussion 
In the  present  study,  we  show  that  human peripheral 
blood CD4 + T  cells activated by allogeneic monocytes in 
the presence of IL-10 for 10 d were rendered unresponsive 
in an antigen-specific fashion. These unresponsive CD4 + T Table  1.  Cytokine  Profile of lL-lO-induced Anergic T Cells 
cpm  IL-2  IL-4  IL-5  IL-10  TNF-o~  IFN-~/  GM-CSF 
pg/ml  pg/ml  pg/ml  pg/ml  ng/ml  ng/mI  pg/ml 
CD3  Control 
cells  42,369  875  --- 59  <40  80 •  23  1,067  •  226  10.5  •  0.9  5.5  -  0.6  1,245  •  687 
Anergic 
cells  2,635  <40  <40  <20  <50  <0.1  <0.1  <50 
PMA +  Ca  2+  Control 
ionophore  cells  147,217  2,121  -  317  <40  841  _  127  51  ___ 27  21.6  •  5.1  7.6 -  3.1  2,721  -  635 
Anergic 
cells  169,321  1,921  +  427  <40  1,517  -4- 415  117  -4- 4.3  18.4  --- 3.6  8.4  -  2.6  1,615  -  317 
Monocytes  Control 
cells  32,236  617  -  42  <40  64 +  15  897  +  125  9.2  •  0.5  2.3 •  0.1  987  •  98 
Anergic 
cells  869  <40  <40  <20  <50  <0.1  <0.1  <50 
CD4 § T cells were activated with either cross-linked  anti-CD3 mAbs, allogeneic monocytes in the absence (control cells) or presence  (anergic cells) 
oflL-10 (100 U/ml). Cells were kept in culture  for 10 d, washed,  and restimulated with cross-linked anti-CD3 mAbs (10 p.g/ml)  or PMA (1 pg/ml) 
and Ca  2+ ionophore (A23187,  500  ng/ml) or allogeneic  PBMC, respectively.  Supematants  were harvested  after 24 h and the levels of cytokines 
were analyzed by ELISA. To measure  cell proliferation,  cells were pulsed with [3H]Tdl~  for 12 h at the end of day 3 for cells activated  with cross- 
linked anti-CD3 mAbs, or at the end of day 5 for cells activated  with allogeneic  monocytes. Results are from one representative  experiment out of 
three. 
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Figure  6.  Cytofluorometric analysis of anerglc  T  cells. CD4  + T  cells 
were activated with cross-linked anti-CD3 mAbs in the absence or pres- 
ence of IL-10  (100 U/ml) for 10 d and the expression of CD3, CD28, 
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cells failed to proliferate and to produce cytokines when re- 
stimulated  by  the  same  allogeneic  monocytes.  However, 
these T  cell populations proliferated normally in response to 
third-party alloantigens. A  comparable state ofT  cell anergy 
was  induced  after activation of CD4 +  T  cells by anti-CD3 
mAbs in the presence of IL-10. The IL-10-induced anergy 
was  dose  dependent  and  lasted  for  more  than  24  d  after 
withdrawal  of IL-10,  which  was  the  maximal  time  period 
analyzed.  Furthermore,  the  anergic  state  could  not  be  re- 
versed  by  exogenous  IL-2  or  the  addition  of anti-CD28 
mAbs.  In addition,  T  cell anerg'y could not be induced  by 
stimulation  with allogeneic monocytes  or anti-CD3  mAbs 
in the presence  of anti-IL-2R mAbs.  These results indicate 
that T  cell anergy is specifically induced by IL-10 and is not 
simply  related  to  downregulation  of IL-2  production  by 
these cells (16, 24).  Recently it was shown that T  cell unre- 
sponsiveness  to  alloantigens  induced  in  MLR  in  the  ab- 
sence of costimulation could be reversed by exogenous IL-2 
and stimulation of the CD2  pathway  (25).  Whether  IL-10- 
induced  T  cell anergy  can be restored  in this way remains 
to be determined. 
IL-10-induced  T  cell anergy  differs  clearly from  T  cell 
unresponsiveness  induced  by  incubation  of mouse  or  hu- 
man  T  cells with antigenic peptides  in the absence  of pro- 
and  HLA-DR was  analyzed  before  and  after  reactivation  with  cross- 
linked anti-CD3 mAbs for 24 h. (Black lines) Control T cells cultured  in 
the absence of IL-10;  (dotted histograms) anergic  T  cells cultured  in the 
presence of IL-10. Before activation 
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Figure 7.  IL2P,  c~ chain expression on anergic T 
cells. CD4 +  T  cells were  activated with  cross- 
linked anti-CD3 mAbs in the presence or absence 
of IL-10 (100 U/ml) for 3 d (a) or 10 d (b) and re- 
stimulated with either cross-linked anti-CD3 mAbs 
alone or with  cross-linked anti-CD3  mAbs plus 
IL-2  (100 U/ml).  The  expression of the  CD25 
molecule was  analyzed 24  h  after activation by 
cytofluorometry. (Black lines)  Control isotype; (dot- 
ted histograms)  labeling with anti-CD25 mAbs. 
fessional APC (19, 25, 26). In this latter case, the expression 
of the  TCR/CD3  complex  was  downregulated  and  no 
mobilization  of [Ca2+]i was  observed  (26,  27),  unlike  the 
findings with  IL-10-induced anergy.  On  the  other  hand, 
CD4 + T  cells anergized by IL-10 share many characteristics 
with anergic T  cells described in routine models of anergy 
induced by lack of costimulatory signals  (16,  18,  28,  29). 
These anergic cells failed to proliferate and to produce IL-2, 
but they had a normal expression of CD3 or CD28 surface 
molecules, and normal calcium fluxes after mobilization of 
the TCR./CD3 complex (18). However, T  ceil anergy in- 
duced by IL-10 is much more profound than that described 
in these routine models,  since the proliferative response of 
anergic  T  cells  cannot be  restored  by addition  of IL-2 or 
anti-CD28 mAbs. Furthermore,  not only IL-2 production, 
but  also  the  production  of IFN-y,  IL-5,  IL-10,  TNF-(x, 
and  GM-CSF by these anergic cells was impaired.  There- 
fore, induction ofT  cell anergy by IL-10 is not due simply 
to inhibition of IL-2 production and prevention of produc- 
tive  CD28-CD80/CD86  interactions.  IL-10-anergized  T 
cells are also different from T  ceils that undergo apoptosis 
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or anergized T  cells able to secrete cytokines in the absence 
of proliferation  (24,  30).  In fact, no significant cell loss by 
apoptosis was  observed in  the  anergic  T  ceils  cultured  in 
IL-10, and the anergic T  cells were viable as proven by the 
normal proliferation after stimulation with Ca  2+ ionophore 
and PMA. 
Overall,  our  data  indicate  that  signaling  through  the 
TCR/CD3  complex is selectively impaired in IL-10-aner- 
gized  T  cells.  This  is  not  due  to  downregnlation  of the 
TCR  or  CD28  molecules,  since  the  anergic  T  cells  ex- 
pressed levels of TCR/CD3  and CD28 that were compa- 
rable  with  those  of untreated  T  cells.  Furthermore,  al- 
though  stimulation  of the  anergic  T  cells  through  the 
TCR/CD3  complex did not result in cell proliferation and 
cytokine production,  a  clear increase in CD3,  CD28,  and 
class  II MHC  expression  was  observed  after restimulation 
of the cells with anti-CD3 mAbs, indicating that some de- 
gree of TCR  activation occurred in these anergic cells. 
This  notion  was  further  supported  by  the  observation 
that  Ca  2+  fluxes  in  anergized  T  cells  were  normal  after 
CD3  activation,  demonstrating  that  calcineurin-mediated 3.11 
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Figure 8.  Calcium mobilization analysis  in anergic T cells. CD4 + T cells were activated with anti-CD3 mAbs  in the absence (a) or presence (b) of IL- 
10 (100 U/nil) for 10 d and loaded with indo-1/AM. As indicated, anti-CD3 mAbs (10 p.g/ml), goat anti-mouse IgG (1 ~g/ml), or Ca  2+ ionophore 
(500 ng/ml) were sequentially added into the cuvette and the rise of [Ca2+]i was analyzed  by spectrofluorimetry and measured by the ratio of emission at 
405/485. One representative  experiment out of three is shown. 
signaling is not affected. Importantly, a complete reversal of 
anergy was  observed after activation with PMA and Ca  2+ 
ionophore. These stimuli, which circumvent TCR  activation, 
completely restored proliferation and cytokine secretion by 
anergic  cells.  These  findings  suggest  that  IL-10  interferes 
with proximal events in the TCP,. signaling pathway, prob- 
ably  at  the  level  of  P,.as-microtubule-associated  protein 
(MAP) kinase activation, as is suggested for mouse models 
of anergy  induction  (31-33).  Alternatively, although  the 
signahng cascade downstream of p21ras seems to be intact, 
it cannot be excluded that IL-10 induces a negative regula- 
tor of this signaling pathway. 
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T  cells  rendered  anergic  by  activation  and  incubation 
with IL-10 for 9-10  d  failed, in contrast to their untreated 
counterparts,  to  upregulate  the  IL-2tkcx  chain  expression 
when  restimulated  with  anti-CD3  mAbs.  It  is  therefore 
tempting to speculate that this defect in upregulation of IL- 
21:(ci chain expression accounts for the failure of exogenous 
IL-2 to reverse anergy. This hypothesis is supported by the 
observation that T  cells rendered anergic by activation and 
incubation  with  IL-10  for  3  d,  and  which  still expressed 
CD25, could be rescued by exogenous IL-2. A  comparable, 
but less profound, defect in IL-2 use has been reported for 
superantigen-induced  T  cell  unresponsiveness  in  TCP,.- transgenic mice (34). Taken together, these data suggest that 
anergy induction may be permanent if induced properly. 
Transplantation  tolerance,  the  long-term  acceptance  of 
grafted  tissue  in  the  absence  of continuous  immunosup- 
pression, remains an elusive goal in humans, but it has been 
achieved  in  animal  models  using  various  approaches  (29, 
35,  36).  Among the mechanisms responsible  for induction 
of tolerance  to  aUoantigens,  a  nondeletional  mechanism 
that results in functional inactivation of the appropriate al- 
loreactive T  cells has been proposed. This functional inacti- 
vation  can  be  achieved by blocking costimulatory  signals 
provided by accessory molecules expressed on APC and T 
cells  (37-40). Prevention of the interaction between CD28 
and either CD80 or CD86 appears to be critical for this in- 
duction  of anergy,  but  blockade  of other  costimulatory 
molecules such as CD2  or ICAM-1  may also be involved 
(25,  39-41).  However, the fact that the tolerance induced 
in these experimental models is long-lasting and potentially 
irreversible  suggests  underlying  mechanisms  that  may  be 
more complex than the mere lack of a second signal to the 
Th cell upon recognition of alloantigens.  It is possible that 
some form of active suppression is mediated by cytokines. 
These cytokines may contribute to the induction or main- 
tenance  of T  cell anergy not only by downregulating  co- 
stimulatory molecules, but also by inducing the expression 
of negative  regulators,  such as  CTLA-4  (42).  In humans, 
SCID  patients  are  one  of the  few  examples  in  which  in 
vivo  tolerance  is  obtained  after  HLA-mismatched  trans- 
plantation.  This tolerance is due to a nondeletional mecha- 
nism that is responsible for the functional inactivation of T 
cells specifically recognizing the host alloantigens  (43,  44). 
These  host-reactive  T  cells  secrete high levels of IL-10 in 
vitro,  and  high  IL-10 levels  have  been  observed  in vivo, 
suggesting that IL-10 may play a role in the induction and 
maintenance of tolerance (15). Based on the present results, 
it is tempting to conclude that the high levels of IL-10 ob- 
served in these patients render the host-reactive T  cells  an- 
ergic in vivo.  High levels  of IL-10 secretion  before  trans- 
plantation  have  been  also  shown  to  correlate  with  a 
successful outcome of the transplant  (45),  further support- 
ing the  hypothesis that  IL-10 might play a  role in the  in- 
duction of tolerance. 
Collectively,  our data suggest that  IL-10 might have an 
important role in transplantation  tolerance by inducing an- 
ergy to  donor-  and/or  host-specific  alloantigens.  In addi- 
tion,  they indicate  that IL-10 may have a potential  clinical 
use in preventing or reducing GVHD  and allograft rejec- 
tion. 
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